Moleculin Biotech Stock EBITDA
| MBRX Stock | USD 4.28 0.18 4.04% |
Moleculin Biotech fundamentals help investors to digest information that contributes to Moleculin Biotech's financial success or failures. It also enables traders to predict the movement of Moleculin Stock. The fundamental analysis module provides a way to measure Moleculin Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moleculin Biotech stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -29.5 M | -31 M |
Moleculin | EBITDA |
Moleculin Biotech Company EBITDA Analysis
Moleculin Biotech's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Moleculin Biotech EBITDA | (29.5 M) |
Most of Moleculin Biotech's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moleculin Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Moleculin EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Moleculin Stock properly, considering its historical fundamentals such as EBITDA. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Moleculin Ebitda
According to the company disclosure, Moleculin Biotech reported earnings before interest,tax, depreciation and amortization of (29.5 Million). This is 103.36% lower than that of the Biotechnology sector and 129.46% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.76% higher than that of the company.
Moleculin EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moleculin Biotech's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics of similar companies.Moleculin Biotech is currently under evaluation in ebitda category among related companies.
Moleculin Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Moleculin Biotech from analyzing Moleculin Biotech's financial statements. These drivers represent accounts that assess Moleculin Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moleculin Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 37.3M | 47.1M | 50.0M | 30.3M | 25.4M | 24.2M | |
| Enterprise Value | 26.9M | 32.2M | (20.8M) | (12.4M) | 2.5M | 2.3M |
Moleculin Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Moleculin Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moleculin Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moleculin Biotech's value.| Shares | Tower Research Capital Llc | 2023-12-31 | 7.2 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 6.3 K | Sandy Spring Bank | 2023-12-31 | 1.3 K | Advisor Group Holdings, Inc. | 2023-12-31 | 968 | Cva Family Office, Llc | 2023-12-31 | 500 | North Star Investment Management Corp | 2023-12-31 | 250 | Wells Fargo & Co | 2023-12-31 | 229 | Nbc Securities Inc | 2023-09-30 | 200 | Bank Of America Corp | 2023-12-31 | 138 | Armistice Capital, Llc | 2023-12-31 | 3.2 M | Vanguard Group Inc | 2023-12-31 | 1.1 M |
Moleculin Fundamentals
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | (13.44 M) | ||||
| Shares Outstanding | 2.23 M | ||||
| Shares Owned By Insiders | 4.64 % | ||||
| Shares Owned By Institutions | 15.51 % | ||||
| Number Of Shares Shorted | 44.95 K | ||||
| Price To Earning | (3.81) X | ||||
| Price To Book | 0.40 X | ||||
| EBITDA | (29.5 M) | ||||
| Net Income | (29.77 M) | ||||
| Cash And Equivalents | 58 M | ||||
| Cash Per Share | 2.03 X | ||||
| Total Debt | 574 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 11.71 X | ||||
| Cash Flow From Operations | (24.1 M) | ||||
| Short Ratio | 0.66 X | ||||
| Earnings Per Share | (15.15) X | ||||
| Target Price | 35.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 1.85 | ||||
| Market Capitalization | 9.53 M | ||||
| Total Asset | 38.22 M | ||||
| Retained Earnings | (131.6 M) | ||||
| Working Capital | 19.46 M | ||||
| Current Asset | 28.09 K | ||||
| Current Liabilities | 772.79 K | ||||
| Net Asset | 38.22 M |
About Moleculin Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Moleculin Biotech Piotroski F Score and Moleculin Biotech Altman Z Score analysis. For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Moleculin Stock analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.15) | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.